Double-digit 2025 revenue growth at Cumberland (Nasdaq: CPIX) with loss reduction
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Cumberland Pharmaceuticals reported strong 2025 growth with improving profitability and cash generation. Net revenues reached $44.5 million for 2025, up 18% year over year, including $13.7 million in fourth-quarter revenue, a 31% increase over the prior-year quarter. Key brands contributed $10.5 million from Kristalose, $11.9 million from Sancuso, $9.5 million from Vibativ, $4.7 million from Caldolor and $3.3 million from Talicia.
The company’s 2025 net loss narrowed to $2.9 million, a $3.6 million improvement from 2024, while Adjusted Earnings were $1.7 million, a $2.7 million improvement. Operating cash flow turned positive at $4.9 million. At December 31, 2025, Cumberland reported $76.8 million in total assets, $52.3 million in liabilities and $24.9 million in shareholders’ equity, including $11.4 million in cash and a reduced credit facility balance of $5.2 million, down $10 million from year-end 2024.
Strategically, Cumberland expanded Vibativ into China and Saudi Arabia, gained approval for an ibuprofen injection in Mexico, and added Talicia via a co-commercialization agreement. Caldolor received a permanent CMS J-code (J1741), and the ifetroban FIGHT DMD Phase II trial delivered positive top-line results, with the DMD program receiving Orphan Drug, Rare Pediatric Disease and Fast Track designations.
Positive
- Strong top-line growth and improved earnings: 2025 net revenues rose 18% to $44.5 million, with Adjusted Earnings improving to $1.7 million from a prior-year loss and the net loss narrowing by $3.6 million.
- Cash flow and balance sheet strengthening: Operating cash flow improved to $4.9 million, and revolving credit facility debt was reduced by $10 million, ending 2025 with $5.2 million outstanding and $24.9 million in shareholders’ equity.
Negative
- None.
Insights
Revenue grew double digits, losses shrank, and cash flow turned positive in 2025.
Cumberland Pharmaceuticals delivered net revenue of
Profitability metrics improved meaningfully. The net loss narrowed to
Strategic execution included international launches for Vibativ, an ibuprofen injection approval in Mexico, and the Talicia co-commercialization in the U.S. The positive FIGHT DMD ifetroban Phase II results and FDA Fast Track, Orphan Drug and Rare Pediatric Disease designations highlight a developing pipeline asset. Subsequent filings may further detail commercialization progress and additional clinical milestones.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | |||||||||
(Address of Principal Executive Offices)
(615 ) 255-0068
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On March 3, 2026, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release which provided a company update and the financial results for the three months and year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02.
This information is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless specifically incorporated by reference in a document filed under the Securities Act of 1933, as amended, or the Exchange Act. By filing this report on Form 8-K and furnishing this information, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by Item 2.02.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | Description | |||||||
99.1 | Press release dated March 3, 2026 | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Cumberland Pharmaceuticals Inc. | ||||||||||||||||||||
Dated: March 3, 2026 | By: | /s/ John Hamm | ||||||||||||||||||
| John Hamm | ||||||||||||||||||||
| Chief Financial Officer | ||||||||||||||||||||
CUMBERLAND PHARMACEUTICALS REPORTS
31.1% FOURTH QUARTER 2025 REVENUE GROWTH
Cumberland to highlight 2025 financial, international, portfolio and clinical progress
NASHVILLE, Tenn. (Tuesday, March 3, 2026) – Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $13.7 million during the fourth quarter of 2025, a 31% increase over the prior year period.
Net revenues for the full year 2025 were $44.5 million an 18% increase over the prior year period, achieving the company’s target of double digit revenue growth. Cumberland ended the year with $76.8 million in total assets, $52.3 million in liabilities and $24.9 million of shareholders’ equity.
The net loss for 2025 was $2.9 million, which was an improvement of $3.6 million from the prior year. When noncash items are added back the Adjusted Earnings for the full year were $1.7 million, a $2.7 million improvement over the prior year. In addition, cashflow from operations was $4.9 million in 2025 representing a $5.5 million increase over 2024.
“We are pleased with Cumberland’s strong financial performance in 2025, and the progress made across our commercial and development portfolio,” said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. “We delivered solid revenue growth, expanded our international presence, strengthened our commercial platform with the addition of Talicia® and achieved important reimbursement and clinical milestones. These accomplishments reflect the strength of our strategy and position Cumberland for continued growth as we work together to provide unique products that improve the quality of patient care.”
2025 HIGHLIGHTS INCLUDE:
International Expansion
In February 2025, Cumberland announced that its Vibativ® product received approval from the regulatory authorities in China, the world’s second-largest pharmaceutical market. The announcement follows an agreement that provides SciClone Pharmaceuticals with the exclusive rights to register, promote and distribute the product to patients in the Chinese market.
In September 2025, Cumberland announced the launch of Vibativ in Saudi Arabia. The product launch follows an agreement with Tabuk Pharmaceutical Manufacturing Company to introduce Vibativ into the Middle East. The arrangement provided Tabuk exclusive rights to distribute Vibativ in Saudi Arabia and Jordan, with the option to expand into other countries in the region. Tabuk has obtained the final approvals needed to commercialize Vibativ in Saudi Arabia.
In October 2025, Cumberland’s ibuprofen injection product received regulatory approval in Mexico. The company previously announced its partnership with PiSA Farmaceutica, a well-established Mexican pharmaceutical firm. Under the agreement, PiSA is provided with the exclusive supply and distribution rights for the ibuprofen product in the Mexican market while Cumberland provides regulatory and manufacturing support. PiSA plans to introduce the product, making it accessible for a variety of clinical uses in Mexican healthcare facilities.
Expanded Commercial Portfolio
In October 2025, Cumberland announced arrangements with RedHill Biopharma Ltd. to jointly commercialize Talicia®, marking the latest addition to its commercial product portfolio. The FDA-approved oral capsule is indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults, a bacterial infection and leading risk factor for gastric cancer.
Through a co-commercialization agreement, Cumberland assumed responsibility for the distribution and sale of Talicia in the U.S. Cumberland records Talicia product sales and equally shares Talicia’s net revenues. Cumberland will provide an annual investment to cover certain distribution, marketing and sales costs. Leveraging its established field sales division, Cumberland leads the sales promotion for Talicia with the goal to increase the number of patients who benefit from the treatment.
Talicia is the only all-in-one treatment containing omeprazole, amoxicillin and rifabutin, and is now recommended as a first-line therapy in the American College of Gastroenterology (ACG) clinical guidelines. Talicia is patent protected through 2042 and received eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation.
CMS Establishes Reimbursement for Caldolor® Through Permanent J-Code
Caldolor® received a key reimbursement milestone with the establishment of its permanent J-code, J1741, in December 2025. The J-Code is now officially linked to a CMS reimbursement price. This designation enables healthcare providers to access a clearly defined and reimbursable pathway for Caldolor, supporting its continued adoption across hospital and clinical settings.
As the nation continues to address the opioid crisis, Caldolor offers an important non-opioid option for managing pain and fever. The availability of CMS reimbursement through J1741 enhances provider access to this therapy, supporting safer pain management strategies and helping reduce reliance on opioid medications.
This reimbursement milestone reinforces Caldolor’s role as a clinically proven, non-opioid alternative and strengthens its position within hospital protocols and opioid-sparing treatment initiatives. It also supports broader access for patients while advancing efforts to improve outcomes and promote responsible pain management.
Clinical Top-Line Study Results
In early 2025, Cumberland announced positive top-line results from its FIGHT DMD clinical trial. The study evaluated ifetroban, a novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease – the leading cause of death in DMD patients. It marks a breakthrough for these patients, as it is the first successful Phase II study specifically targeting the cardiac complications of their condition. Ifetroban has been studied in over 1,400 subjects across multiple clinical trials, demonstrating a well-established safety profile.
The trial enrolled 41 DMD patients who received either low dose ifetroban (150 mg per day), high dose ifetroban (300 mg per day) or placebo. The study's primary endpoint was an improvement in the heart's left ventricular ejection fractions (LVEF). Key findings included:
•High dose ifetroban treatment resulted in an overall 3.3% improvement in LVEF.
•The high dose ifetroban group showed an increase in 1.8% in LVEF, while the study placebo group showed an expected decline in LVEF of 1.5%.
•When compared with propensity matched natural history controls, the difference was even more pronounced, with the high dose treatment providing a significant 5.4% overall improvement in LVEF, as the control patients experienced a 3.6% decline in LVEF.
•Both doses of ifetroban were well-tolerated, with no serious drug-related events.
The top-line FIGHT DMD study findings were selected for a late-breaking presentation at the Muscular Dystrophy Association’s Clinical & Scientific Conference in March 2025 and they were presented at the Parent Project Muscular Dystrophy Annual Conference in June 2025.
Cumberland held two meetings with the FDA to discuss the study results and remaining development path forward. This DMD program received Orphan Drug and Rare Pediatric Disease designation from the FDA in late 2024. In addition, the FDA also provided Fast Track Designation for the Program in early 2026.
FINANCIAL RESULTS:
Net Revenue: For 2025, net revenues were $44.5 million and included $10.5 million for Kristalose®, $11.9 million for Sancuso®, $9.5 million for Vibativ®, $4.7 million for Caldolor® and $3.3 million for Talicia®.
Operating Expenses: Total operating expenses for 2025 were $47.3 million.
Net Income (Loss): The net loss for 2025 was $2.9 million, an improvement of $3.6 million over the prior year.
Adjusted Earnings: Adjusted earnings for 2025 were $1.7 million, a $2.7 million improvement over 2024.
Balance Sheet: On December 31, 2025, Cumberland had $76.8 million in total assets, including $11.4 million in cash and cash equivalents. Liabilities totaled $52.3 million, including $5.2 million on the company’s credit facility, which represented a reduction of $10 million in debt, compared to the end of 2024. Total shareholders’ equity was $24.9 million on December 31, 2025.
EARNINGS REPORT CALL:
A conference call will be held today, March 3, 2026, at 4:30 p.m. Eastern Time to provide a company update and discuss the financial results.
The link to register is https://register-conf.media-server.com/register/BI6effc1a9cae9445f9bb0d60817870ffa.
Registered participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a “Call Me” option to have the system automatically call them at the start of the conference.
A replay of the call will be available for one year and can be accessed via Cumberland’s website or by visiting: https://edge.media-server.com/mmc/p/w5m9usns.
ABOUT CUMBERLAND PHARMACEUTICALS:
Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company’s portfolio of FDA-approved brands includes:
•Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
•Caldolor® (ibuprofen) injection, for the treatment of pain and fever;
•Kristalose® (lactulose) oral, a prescription laxative, for the treatment of constipation;
•Sancuso® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
•Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;
•Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and
•Talicia® (omeprazole, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection.
The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Duchenne Muscular Dystrophy, Systemic Sclerosis and Pulmonary Fibrosis.
For more information on Cumberland’s approved products, including full prescribing information, please visit the links to the individual product websites, which can be found on the company’s website at www.cumberlandpharma.com.
About Acetadote® (acetylcysteine) Injection
Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is approved in the United States to treat overdose of acetaminophen, a common ingredient in many over-the-counter medications. Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. For full prescribing and safety information, visit www.acetadote.com.
About Caldolor® (ibuprofen) Injection
Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and the management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever. It was the first FDA-approved intravenous therapy for fever.
Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other non-steroidal anti-inflammatory drugs (NSAIDs) as well as patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. For full prescribing and safety information, including boxed warning, visit www.caldolor.com.
About Kristalose® (lactulose) Oral Solution
Kristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing and safety information, visit www.kristalose.com.
About Sancuso® (granisetron) Transdermal System
Sancuso is the only skin patch approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately and/or highly emetogenic chemotherapy. When applied 24 to 48 hours before receiving chemotherapy, the Sancuso patch slowly and continuously releases the medicine contained in the adhesive through clean and intact skin areas into the patient’s bloodstream. It can prevent CINV for chemotherapy regimens of up to five consecutive days. For full prescribing and safety information, visit www.sancuso.com.
About Vaprisol® (conivaptan hydrochloride) Injection
Vaprisol is an intravenous treatment for hyponatremia used in the critical care setting. Hyponatremia is an electrolyte disturbance in which sodium ion concentration in blood plasma is lower than normal. This can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia. The product is a vasopressin receptor antagonist that raises serum sodium levels and promotes free water secretion. Vaprisol is contraindicated in patients with hypovolemic hyponatremia. The coadministration of Vaprisol with potent CYP3A inhibitors, such as ketoconazole, itraconazole, clarithromycin, ritonavir and indinavir, is contraindicated. For full prescribing and safety information, including boxed warning, visit www.vaprisol.com.
About Vibativ® (telavancin) for Injection
Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. Intravenous unfractionated heparin sodium is contraindicated with Vibativ administration due to artificially prolonged activated partial thromboplastin time (aPTT) test results for up to 18 hours after Vibativ administration. Vibativ is contraindicated in patients with a known hypersensitivity to telavancin. For more information, please visit www.vibativ.com.
About Talicia®
Talicia® is an FDA approved oral capsule for the treatment of Helicobacter pylori (H. pylori) infection in adults, a bacterial infection of the stomach and leading risk factor for gastric cancer. Talicia is listed as a first line option in the 2024 ACG Guideline for the treatment of H. pylori and features three key advantages: 1) high eradication rates - >90% in confirmed adherent patients, 2) the simplicity of an all-in-one capsule, and 3) low resistance to the two antibiotics - amoxicillin and rifabutin. For more information, please visit www.talicia.com.
FORWARD LOOKING STATEMENTS:
This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland’s current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the Company’s intent, belief or expectations, and can be identified by the use of terminology such as “may,” “will,” “expect,” “believe,” “intend,” “plan,” “estimate,” "goal", “should,” “seek,” “anticipate,” “look forward” and other comparable terms or the negative thereof. As with any business, all phases of Cumberland’s operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland’s operation results. These factors include macroeconomic conditions, including changes in interest rates, inflation, tariffs, competition, an inability of manufacturers to produce Cumberland’s products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the Company’s control as more fully discussed in its most recent annual report on Form 10-K as filed with the U.S. Securities and Exchange Commission (“SEC”), as well as the Company’s other filings with the SEC from time to time. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.
SOURCE: Cumberland Pharmaceuticals Inc.
Investor Contact: | Media Contact: | ||||
Shayla Simpson | Emily Kent | ||||
Cumberland Pharmaceuticals Inc. | Dalton Agency | ||||
(615) 255-0068 | (540) 621-5448 | ||||
- MORE -
CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Consolidated Balance Sheets
December 31, 2025 and 2024
(Unaudited)
| 2025 | 2024 | |||||||||||||
| ASSETS | ||||||||||||||
| Current assets: | ||||||||||||||
| Cash and cash equivalents | $ | 11,444,693 | $ | 17,964,184 | ||||||||||
| Accounts receivable, net | 16,944,780 | 11,701,466 | ||||||||||||
| Inventories, net | 6,225,518 | 3,999,995 | ||||||||||||
| Prepaid and other current assets | 2,445,276 | 2,786,513 | ||||||||||||
| Total current assets | 37,060,267 | 36,452,158 | ||||||||||||
| Non-current inventories | 9,253,090 | 11,005,499 | ||||||||||||
| Property and equipment, net | 264,724 | 277,365 | ||||||||||||
| Intangible assets, net | 14,027,921 | 17,973,449 | ||||||||||||
| Goodwill | 914,000 | 914,000 | ||||||||||||
| Operating lease right-of-use assets | 8,343,832 | 6,176,923 | ||||||||||||
| Investment in co-commercialization | 3,986,780 | — | ||||||||||||
| Other assets | 2,973,378 | 2,784,016 | ||||||||||||
| Total assets | $ | 76,823,992 | $ | 75,583,410 | ||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Accounts payable | $ | 18,567,546 | $ | 13,914,266 | ||||||||||
| Operating lease current liabilities | 467,774 | 356,508 | ||||||||||||
| Revolving line of credit - current | — | 5,100,000 | ||||||||||||
| Other investment liabilities | 5,074,504 | — | ||||||||||||
| Other current liabilities | 12,635,095 | 12,250,955 | ||||||||||||
| Total current liabilities | 36,744,919 | 31,621,729 | ||||||||||||
| Revolving line of credit - long term | 5,240,733 | 10,176,170 | ||||||||||||
| Operating lease non-current liabilities | 4,471,965 | 4,939,739 | ||||||||||||
| Other long-term liabilities | 5,822,153 | 6,299,795 | ||||||||||||
| Total liabilities | 52,279,770 | 53,037,433 | ||||||||||||
| Commitments and contingencies | ||||||||||||||
| Equity: | ||||||||||||||
| Shareholders’ equity: | ||||||||||||||
Common stock – no par value; 100,000,000 shares authorized; 14,956,627 and 13,952,624 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 51,684,381 | 46,821,425 | ||||||||||||
| Accumulated deficit | (26,804,059) | (23,967,931) | ||||||||||||
| Total shareholders’ equity | 24,880,322 | 22,853,494 | ||||||||||||
| Noncontrolling interests | (336,100) | (307,517) | ||||||||||||
| Total equity | 24,544,222 | 22,545,977 | ||||||||||||
| Total liabilities and equity | $ | 76,823,992 | $ | 75,583,410 | ||||||||||
CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Consolidated Statements of Operations
(Unaudited)
| Three months ended December 31, | Years ended December 31, | |||||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||||||
| Net revenues | $ | 13,678,651 | $ | 10,435,569 | $ | 44,521,431 | $ | 37,867,945 | ||||||||||||||||||
| Costs and expenses: | ||||||||||||||||||||||||||
| Cost of products sold | 2,241,344 | 1,976,473 | 6,667,207 | 6,585,972 | ||||||||||||||||||||||
| Selling and marketing | 6,208,695 | 4,222,554 | 19,098,153 | 17,023,023 | ||||||||||||||||||||||
| Research and development | 1,549,656 | 1,292,671 | 5,566,498 | 4,816,206 | ||||||||||||||||||||||
| General and administrative | 4,036,913 | 3,326,466 | 11,946,909 | 11,126,901 | ||||||||||||||||||||||
| Amortization and impairment | 1,013,245 | 1,459,444 | 4,034,657 | 4,748,252 | ||||||||||||||||||||||
| Total costs and expenses | 15,049,853 | 12,277,608 | 47,313,424 | 44,300,354 | ||||||||||||||||||||||
| Operating loss | (1,371,202) | (1,842,039) | (2,791,993) | (6,432,409) | ||||||||||||||||||||||
| Interest income | 91,967 | 106,667 | 476,748 | 334,444 | ||||||||||||||||||||||
| Equity in loss of investee | (13,220) | — | (13,220) | — | ||||||||||||||||||||||
| Other income - gain on insurance proceeds | — | — | — | 237,089 | ||||||||||||||||||||||
| Interest expense | (112,942) | (223,261) | (495,990) | (605,508) | ||||||||||||||||||||||
| Loss before income taxes | (1,405,397) | (1,958,633) | (2,824,455) | (6,466,384) | ||||||||||||||||||||||
| Income tax (expense) benefit | (23,245) | 56,996 | (40,256) | 22,669 | ||||||||||||||||||||||
| Net loss | (1,428,642) | (1,901,637) | (2,864,711) | (6,443,715) | ||||||||||||||||||||||
| Net (income) loss at subsidiary attributable to noncontrolling interests | 16,950 | (2,177) | 28,583 | (36,055) | ||||||||||||||||||||||
| Net loss attributable to common shareholders | $ | (1,411,692) | 0 | $ | (1,903,814) | $ | (2,836,128) | $ | (6,479,770) | |||||||||||||||||
| Loss per share attributable to common shareholders: | ||||||||||||||||||||||||||
| Basic | $ | (0.09) | $ | (0.14) | $ | (0.19) | $ | (0.46) | ||||||||||||||||||
| Diluted | (0.09) | (0.14) | (0.19) | (0.46) | ||||||||||||||||||||||
| Weighted-average common shares outstanding: | ||||||||||||||||||||||||||
| Basic | 14,956,627 | 13,971,228 | 14,854,619 | 14,060,272 | ||||||||||||||||||||||
| Diluted | 14,956,627 | 13,971,228 | 14,854,619 | 14,060,272 | ||||||||||||||||||||||
CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows
Years ended December 31, 2025 and 2024
(Unaudited)
| 2025 | 2024 | |||||||||||||
| Cash flows from operating activities: | ||||||||||||||
| Net loss | $ | (2,864,711) | $ | (6,443,715) | ||||||||||
| Adjustments to reconcile net loss to net cash flows provided by (used in) operating activities: | ||||||||||||||
| Depreciation and amortization expense | 4,145,201 | 4,902,560 | ||||||||||||
| Amortization of operating lease right-of-use asset | 1,140,738 | 1,140,738 | ||||||||||||
| Loss on co-commercialization investment | 13,220 | — | ||||||||||||
| Disposal of assets | — | 2,691 | ||||||||||||
| Stock-based compensation | 408,320 | 301,895 | ||||||||||||
| Increase (decrease) in non-cash contingent consideration | 46,569 | (1,460,804) | ||||||||||||
| Increase in cash surrender value of life insurance policies over premiums paid | (142,927) | (139,953) | ||||||||||||
| Noncash interest expense | 23,185 | 28,313 | ||||||||||||
| Life insurance proceeds | — | (237,089) | ||||||||||||
| Net changes in assets and liabilities affecting operating activities: | ||||||||||||||
| Accounts receivable | (5,243,314) | (1,943,290) | ||||||||||||
| Inventories, net | 2,242,616 | 2,408,397 | ||||||||||||
| Other current assets and other assets | (231,829) | 189,112 | ||||||||||||
| Operating lease liabilities | (836,100) | 1,784,089 | ||||||||||||
| Accounts payable and other current liabilities | 6,709,196 | (991,359) | ||||||||||||
| Other long-term liabilities | (477,642) | (153,771) | ||||||||||||
| Net cash provided by (used in) operating activities | 4,932,522 | (612,186) | ||||||||||||
| Cash flows from investing activities: | ||||||||||||||
| Additions to property and equipment | (97,903) | (66,461) | ||||||||||||
| Additions to intangible assets | (84,402) | (113,253) | ||||||||||||
| Net investment in manufacturing | (2,477,192) | — | ||||||||||||
| Other investment | (2,000,000) | — | ||||||||||||
| Increase in cash surrender value of life insurance policies | (47,000) | — | ||||||||||||
| Life insurance policy proceeds received | — | 237,556 | ||||||||||||
| Net cash provided by (used in) investing activities | (4,706,497) | 57,842 | ||||||||||||
| Cash flows from financing activities: | ||||||||||||||
| Borrowings on line of credit | — | 38,488,920 | ||||||||||||
| Payments on line of credit | (10,035,437) | (35,996,894) | ||||||||||||
| Proceeds from ATM offering, net | 5,266,334 | — | ||||||||||||
| Payments made in connection with repurchase of common shares | (263,478) | (579,049) | ||||||||||||
| Cash settlement of contingent consideration | (1,712,935) | (1,716,073) | ||||||||||||
| Net cash provided by (used in) financing activities | (6,745,516) | 196,904 | ||||||||||||
| Net decrease in cash and cash equivalents | (6,519,491) | (357,440) | ||||||||||||
| Cash and cash equivalents, beginning of year | 17,964,184 | 18,321,624 | ||||||||||||
| Cash and cash equivalents, end of year | $ | 11,444,693 | $ | 17,964,184 | ||||||||||
CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Reconciliation of Net Income (Loss) Attributable to Common Shareholders to Adjusted Earnings (Loss) and Adjusted Diluted Earnings (Loss) Per Share
(Unaudited)
| Three months ended December 31, | Three months ended December 31, | |||||||||||||||||||||||||
| 2025 | 2025 | 2024 | 2024 | |||||||||||||||||||||||
| Earnings impact | Earnings per share impact | Earnings impact | Earnings per share impact | |||||||||||||||||||||||
| Net loss attributable to common shareholders | $ | (1,411,692) | $ | (0.09) | $ | (1,903,814) | $ | (0.14) | ||||||||||||||||||
| Less: Net loss (income) at subsidiary attributable to noncontrolling interests | 16,950 | — | (2,177) | — | ||||||||||||||||||||||
| Net loss | (1,428,642) | (0.09) | (1,901,637) | (0.14) | ||||||||||||||||||||||
| Adjustments to net loss | ||||||||||||||||||||||||||
| Income tax benefit | 23,245 | — | (56,996) | — | ||||||||||||||||||||||
| Depreciation and amortization | 1,041,895 | 0.07 | 1,496,394 | 0.11 | ||||||||||||||||||||||
Share-based compensation (a) | 172,160 | 0.01 | 74,812 | 0.01 | ||||||||||||||||||||||
| Interest income | (91,967) | (0.01) | (106,667) | (0.01) | ||||||||||||||||||||||
| Interest expense | 112,942 | 0.01 | 223,261 | 0.02 | ||||||||||||||||||||||
| Adjusted Earnings (loss) and Adjusted Diluted Earnings (loss) Per Share | $ | (170,367) | $ | (0.01) | $ | (270,833) | $ | (0.02) | ||||||||||||||||||
| Diluted weighted-average common shares outstanding: | 14,956,627 | 13,971,228 | ||||||||||||||||||||||||
| Additional Information: | ||||||||||||||||||||||||||
Reduction in the carrying amount of right-of-use assets (b) | $ | 285,184 | $ | 0.02 | $ | 285,184 | $ | 0.02 | ||||||||||||||||||
| Year ended December 31, | Year ended December 31, | |||||||||||||||||||||||||
| 2025 | 2025 | 2024 | 2024 | |||||||||||||||||||||||
| Earnings impact | Earnings per share impact | Earnings impact | Earnings per share impact | |||||||||||||||||||||||
| Net loss attributable to common shareholders | $ | (2,836,128) | $ | (0.19) | $ | (6,479,770) | $ | (0.46) | ||||||||||||||||||
| Less: Net loss (income) at subsidiary attributable to noncontrolling interests | 28,583 | — | (36,055) | — | ||||||||||||||||||||||
| Net loss | (2,864,711) | (0.19) | (6,443,715) | (0.46) | ||||||||||||||||||||||
| Adjustments to net loss | ||||||||||||||||||||||||||
| Income tax (benefit) expense | 40,256 | — | (22,669) | $ | — | |||||||||||||||||||||
| Depreciation and amortization | 4,145,201 | 0.27 | 4,902,560 | $ | 0.35 | |||||||||||||||||||||
Share-based compensation (a) | 408,320 | 0.03 | 301,895 | $ | 0.02 | |||||||||||||||||||||
| Interest income | (476,748) | (0.03) | (334,444) | $ | (0.02) | |||||||||||||||||||||
| Interest expense | 495,990 | 0.03 | 605,508 | $ | 0.04 | |||||||||||||||||||||
| Adjusted Earnings (loss) and Adjusted Diluted Earnings (loss) Per Share | $ | 1,748,308 | $ | 0.12 | $ | (990,865) | $ | (0.07) | ||||||||||||||||||
| Diluted weighted-average common shares outstanding: | 15,145,309 | 14,060,272 | ||||||||||||||||||||||||
| Additional Information: | ||||||||||||||||||||||||||
Reduction in the carrying amount of right-of-use assets (b) | $ | 1,140,738 | $ | 0.08 | $ | 1,140,738 | $ | 0.08 | ||||||||||||||||||
The Company provided the above adjusted supplemental financial performance measures, which are considered “non-GAAP” financial measures under applicable SEC rules and regulations. These financial measures should be considered supplemental to, and not as a substitute for, financial information prepared in accordance with Generally Accepted Accounting Principles (“GAAP”). The definition of these supplemental measures may differ from similarly titled measures used by others.
Because these supplemental financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. A reconciliation of the supplemental financial measures to the most directly comparable GAAP financial measures is included in the tables accompanying this release.
Cumberland’s management believes these supplemental financial performance measures are important as they are used by management, along with financial measures in accordance with GAAP, to evaluate the Company’s operating performance. In addition, Cumberland believes that they will be used by certain investors to measure the Company’s operating results. Management believes that presenting these supplemental measures provides useful information about the Company’s underlying performance across reporting periods on a consistent basis by excluding items that Cumberland does not believe are indicative of its core business performance or reflect long-term strategic activities. Certain of these items are not settled through cash payments and include: depreciation, amortization, share-based compensation expense and income taxes. Cumberland utilizes its net operating loss carryforwards to pay minimal income taxes. In addition, the use of these financial measures provides greater transparency to investors of supplemental information used by management in its financial and operational decision-making, including the evaluation of the Company’s operating performance.
The Company defines these supplemental financial measures as follows:
•Adjusted Earnings: Net income (loss) adjusted for the impact of income taxes, depreciation and amortization expense, share-based compensation, interest income and interest expense.
(a) Represents the share-based compensation of Cumberland.
(b) Represents the straight line reduction in carrying value of right-of-use assets.
•Adjusted Diluted Earnings Per Share: Adjusted loss divided by diluted weighted-average common shares outstanding.
FAQ
How did Cumberland Pharmaceuticals (CPIX) perform financially in 2025?
Cumberland generated $44.5 million in 2025 net revenues, up 18% year over year, with a narrowed net loss of $2.9 million. Adjusted Earnings reached $1.7 million, and operating cash flow improved to $4.9 million, reflecting better profitability and cash generation.
What were Cumberland Pharmaceuticals’ key revenue drivers in 2025?
Cumberland’s 2025 net revenues of $44.5 million were led by $11.9 million from Sancuso, $10.5 million from Kristalose, $9.5 million from Vibativ, $4.7 million from Caldolor and $3.3 million from Talicia, showing a diversified branded portfolio.
What is Cumberland Pharmaceuticals’ financial position at December 31, 2025?
At December 31, 2025, Cumberland reported $76.8 million in total assets, $52.3 million in liabilities and $24.9 million in shareholders’ equity. Cash and cash equivalents were $11.4 million, and the revolving credit facility balance was $5.2 million, down $10 million year over year.
What international expansion did Cumberland Pharmaceuticals (CPIX) achieve in 2025?
In 2025, Vibativ gained regulatory approval in China and launched in Saudi Arabia under exclusive regional agreements, while an ibuprofen injection product received approval in Mexico. These steps extend Cumberland’s hospital-focused portfolio into major international markets through local partners.
What is Talicia’s role in Cumberland Pharmaceuticals’ 2025 results?
Talicia contributed $3.3 million to 2025 net revenues under a co-commercialization agreement. Cumberland records product sales, shares net revenues equally, leads U.S. promotion and commits annual investments for distribution, marketing and sales, expanding its gastroenterology franchise.
What were the key clinical developments for Cumberland’s ifetroban DMD program?
The FIGHT DMD Phase II trial showed positive top-line results, including improvement in left ventricular ejection fraction with high-dose ifetroban. The Duchenne muscular dystrophy program holds FDA Orphan Drug and Rare Pediatric Disease designations and received Fast Track designation in early 2026.
How did CMS reimbursement change for Caldolor in 2025?
Caldolor received a permanent CMS J-code, J1741, in December 2025, linking the product to a defined reimbursement price. This designation creates a clearer billing pathway for providers and can support broader hospital and clinical adoption of this non-opioid pain and fever treatment.
Filing Exhibits & Attachments
4 documents
Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
CPIX Rankings
CPIX Latest News
CPIX Latest SEC Filings
CPIX Stock Data
72.39M
8.30M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
United States
NASHVILLE,